The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Another big deal, and another payday most of Wall Street's biggest banks missed.
The Pfizer-Medivation deal announced Monday, worth about $14 billion, is the latest sign that boutique banks are rising on Wall Street. In 2016, the smaller banks have been claiming a bigger portion of the profits that come from large-scale mergers and acquisitions, something they have been able to do after claiming some of the top dealmakers from big Wall Street banks.
When Pfizer negotiated to buy the biopharmaceutical company, it was advised by boutiques Guggenheim Securities and Centerview Partners; its target, Medivation, was advised by JPMorgan Securities and Evercore.
That is expected to generate a payday of up to $50 million for Pfizer's advisors, and nearly $60 million for the banks that advised Medivation, said Jeffrey Nassof, director at M&A consulting firm Freeman & Co.
In the first half of 2016, boutique banks saw their wallet share of M&A (that is to say, what portion of revenue from deals that went to banks) rise to 17 percent, just shy of their all-time high on a percentage basis. It's a sign that companies engaging in M&A are less dependent on mega-banks than they once were.
While boutiques — notably, Guggenheim and Centerview — have elbowed top Wall Street firms aside on health-care and pharmaceutical deals, smaller banks have also won the opportunity to work on large technology deals, including Wal-Mart's buy of Jet.com, Microsoft's $26.2 billion buy of LinkedIn and Verizon's deal to acquire Yahoo.
There are still plenty of industries where Wall Street has maintained dominance, however, Nassof points out. They includes businesses like consumer retail and industrials, where boutique banks have done little in the way of taking more M&A business from top banks.